PCM
NKTR icon

Piermont Capital Management’s Nektar Therapeutics NKTR Stock Holding History

Piermont Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-304
Closed -$223K – 179
2018
Q2 		$223K Buy
+304
New +$351K 0.07% 225
2017
Q4 		– Sell
-1,539
Closed -$554K – 254
2017
Q3 		$554K Sell
1,539
-1,513
-50% -$473K 0.18% 145
2017
Q2 		$895K Buy
+3,052
New +$882K 0.26% 160
2016
Q4 		– Sell
-2,072
Closed -$534K – 265
2016
Q3 		$534K Sell
2,072
-1,933
-48% -$498K 0.13% 231
2016
Q2 		$855K Buy
4,005
+1,944
+94% +$435K 0.22% 182
2016
Q1 		$425K Buy
+2,061
New +$396K 0.14% 175

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Piermont Capital Management's NKTR Position: Q3 2018 in Review

Piermont Capital Management sold out of Nektar Therapeutics (NKTR) in Q3 2018, closing a stake of 304 shares — an estimated $223K sold.

Piermont Capital Management first reported a position in NKTR in Q1 2016 and held it in 6 quarters. The position peaked at $895K in Q2 2017. 389 funds tracked by Wall St. Rank hold NKTR as of Q3 2018.

  • Piermont Capital Management reported no remaining Nektar Therapeutics position as of Q3 2018 after selling out during the quarter.
  • Piermont Capital Management sold 304 Nektar Therapeutics shares in Q3 2018, an estimated $223K.
  • Piermont Capital Management first reported a position in Nektar Therapeutics in Q1 2016 and held it in 6 quarters.
  • Piermont Capital Management's Nektar Therapeutics position peaked at $895K in Q2 2017.
  • 389 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q3 2018.

Based on Piermont Capital Management's 13F filing for Q3 2018, filed 6 Nov 2018.